Free Trial

Fate Therapeutics (FATE) Competitors

Fate Therapeutics logo
$0.96 -0.06 (-5.58%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$1.00 +0.04 (+4.04%)
As of 09/12/2025 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FATE vs. PRTA, CRVS, ERAS, ITOS, SLDB, ATXS, NBTX, FULC, CGEM, and KMDA

Should you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Prothena (PRTA), Corvus Pharmaceuticals (CRVS), Erasca (ERAS), iTeos Therapeutics (ITOS), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Nanobiotix (NBTX), Fulcrum Therapeutics (FULC), Cullinan Therapeutics (CGEM), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry.

Fate Therapeutics vs. Its Competitors

Fate Therapeutics (NASDAQ:FATE) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 5.5% of Fate Therapeutics shares are held by insiders. Comparatively, 9.2% of Prothena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Fate Therapeutics presently has a consensus price target of $3.30, suggesting a potential upside of 242.64%. Prothena has a consensus price target of $19.75, suggesting a potential upside of 140.56%. Given Fate Therapeutics' higher possible upside, equities research analysts plainly believe Fate Therapeutics is more favorable than Prothena.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fate Therapeutics
0 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.14
Prothena
1 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.33

Prothena has higher revenue and earnings than Fate Therapeutics. Prothena is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fate Therapeutics$13.63M8.15-$186.26M-$1.45-0.66
Prothena$135.16M3.27-$122.31M-$5.64-1.46

Fate Therapeutics has a net margin of -2,025.05% compared to Prothena's net margin of -2,929.30%. Fate Therapeutics' return on equity of -50.95% beat Prothena's return on equity.

Company Net Margins Return on Equity Return on Assets
Fate Therapeutics-2,025.05% -50.95% -36.76%
Prothena -2,929.30%-62.17%-54.43%

Fate Therapeutics has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Prothena has a beta of -0.04, indicating that its share price is 104% less volatile than the S&P 500.

In the previous week, Fate Therapeutics had 4 more articles in the media than Prothena. MarketBeat recorded 7 mentions for Fate Therapeutics and 3 mentions for Prothena. Fate Therapeutics' average media sentiment score of 1.07 beat Prothena's score of 0.90 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fate Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Prothena
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Fate Therapeutics beats Prothena on 11 of the 16 factors compared between the two stocks.

Get Fate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FATE vs. The Competition

MetricFate TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$117.64M$3.20B$5.87B$10.14B
Dividend YieldN/A2.30%5.68%4.59%
P/E Ratio-0.6621.1774.5225.93
Price / Sales8.15476.06548.33126.97
Price / CashN/A46.6837.5660.44
Price / Book0.349.6112.166.29
Net Income-$186.26M-$53.29M$3.28B$270.77M
7 Day Performance-4.64%0.28%0.87%3.88%
1 Month Performance-14.77%5.73%4.96%4.88%
1 Year Performance-76.04%10.52%60.74%26.01%

Fate Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FATE
Fate Therapeutics
4.0368 of 5 stars
$0.96
-5.6%
$3.30
+242.6%
-74.2%$117.64M$13.63M-0.66550Positive News
PRTA
Prothena
3.2815 of 5 stars
$8.49
-0.7%
$19.75
+132.6%
-60.4%$460.25M$135.16M-1.51130News Coverage
CRVS
Corvus Pharmaceuticals
2.6018 of 5 stars
$5.90
-4.2%
$15.00
+154.2%
+13.6%$459.01MN/A0.0030Positive News
ERAS
Erasca
2.5709 of 5 stars
$1.55
-3.7%
$3.71
+139.6%
-49.0%$456.71MN/A0.00120Analyst Downgrade
ITOS
iTeos Therapeutics
3.4258 of 5 stars
$10.15
flat
$15.50
+52.7%
N/A$448.73M$35M-2.1790Positive News
SLDB
Solid Biosciences
3.0042 of 5 stars
$5.13
-6.7%
$15.00
+192.4%
-30.2%$428.28M$8.09M0.00100Positive News
Analyst Downgrade
ATXS
Astria Therapeutics
3.0247 of 5 stars
$7.43
-1.2%
$29.00
+290.3%
-30.0%$424.39MN/A-3.7030Positive News
NBTX
Nanobiotix
0.6362 of 5 stars
$8.71
+0.1%
$8.00
-8.2%
+91.3%$417.11M$39.18M0.00100News Coverage
Upcoming Earnings
Short Interest ↑
Gap Up
FULC
Fulcrum Therapeutics
2.6414 of 5 stars
$7.27
-5.1%
$7.57
+4.1%
+103.5%$414.34M$80M0.00100News Coverage
Positive News
Short Interest ↓
CGEM
Cullinan Therapeutics
2.2487 of 5 stars
$6.84
-2.1%
$26.80
+291.8%
-62.9%$412.93MN/A0.0030News Coverage
Positive News
Analyst Forecast
KMDA
Kamada
4.5429 of 5 stars
$7.22
+1.1%
$13.00
+80.1%
+29.5%$410.59M$160.95M21.24360Short Interest ↓

Related Companies and Tools


This page (NASDAQ:FATE) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners